Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case

Area of Science:

• Clinical Research Ethics
• Vaccine Development
• Public Health Policy

Background:

• Peru's government sought a COVID-19 vaccine, approving a clinical trial for an inactivated SARS-CoV-2 vaccine.
• A national scandal erupted when the president received the vaccine outside the trial, leading to public outcry.
• The Peruvian National Academy of Medicine formed a commission to investigate ethical breaches and prevent future misconduct.

Purpose of the Study:

• To identify ethical and regulatory violations in a COVID-19 vaccine trial.
• To provide guidance for preventing similar incidents in future public health emergencies.

Main Methods:

• A commission reviewed all available public documents and information.
• A comprehensive final report was generated based on the gathered evidence.

Main Results:

• Six ethical principles were violated, including unauthorized vaccinations and conflicts of interest.
• Five regulatory procedures were ignored, such as inadequate supervision and lack of external oversight.
• Key issues included improper use of vaccine doses, undisclosed conflicts of interest, and unapproved studies.

Conclusions:

• The COVID-19 emergency led to the circumvention of ethical and regulatory standards due to political pressure.
• Regulatory bodies must warn countries about the risks of clinical trials during health emergencies.
• Adherence to proper ethical and regulatory procedures is crucial, even during crises.